A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

Condition:   Differentiated Thyroid Cancer
Interventions:   Drug: Cabozantinib;   Drug: Placebo
Sponsor:   Exelixis
Not yet recruiting

https://ift.tt/2OoMkQo